ORIGINAL ALK Research Projects, selected & Funded by ALK+ Members

Major Research Project Opportunities for Cancer Project Researchers working IN the ALK-Positive specific, TKI, IMMUNOTHERAPY, and related spaces

Lung cancer research is shockingly underfunded relative to most other cancers . . .

. . . particularly when you take into consideration that it is also responsible for the most deaths of any cancer. National funding is still greatly impacted by the persistent misconception, and harsh judgement that it is the patient’s “fault” for having lung cancer, due to smoking. From those meager funds that are allocated, most lung cancer research is directed towards larger segments of the lung cancer population than the 5% of ALK-positive patients. 

This is all why ALK-Positive patients fundraise for their own futures, for groundbreaking ALK-specific research.

Watch the 2020 ALK Summit presentation about the research grants here

  • ALK Positive’s first research partnership was with LUNGevity in 2018. The intention was to fund one project at $200,000 but ALK Positive was able to fund the top three proposals, totaling $600,000. The funded research proposals were two-year projects. Learn more Read about 2018 Grants / Video

  • In 2019/2020, ALK Positive selected a $500,000 2- year project and fundraised more than $1 million through a partnership with the GO2 Foundation for Lung Cancer. Read about 2019 Grants / Video 1/ Video 2

  • In 2020/2021, ALK Positive awarded $1,600,000 in grants to 3 projects, including TWO phase one clinical trials. Read about 2020 Grants/ Video

Learn more about our member-funded research and our advocacy efforts by downloading our latest Poster Presentation here.

researchers

ALK POSITIVE SEEKS TO PARTNER WITH ENTITIES WHO ARE FURTHERING ALK-positive lung cancer TREATMENT, AS WELL AS MEDICAL PROFESSIONALS THAT PLAY THE VITAL ROLE OF FIRST CONTACT FOR NEW PATIENTS.

A priority for ALK Positive is to fund proposals that seek to overcome or prevent the mechanisms of resistance that develop with all ALK-positive lung cancer targeted therapies. By overcoming or preventing resistance, we hope to transform ALK-positive lung cancer into a manageable, chronic condition.

If you are a researcher or other potential partner, please contact us here.

We also release press release annually that call for submissions for applications for our research grants, of up to $2 million dollars. Follow us on these social media pages for the next call for submissions.